Business Context and Reporting Period
Company: Cardiff Oncology, Inc. (CRDF)
Filing Type: Form 8-K (Current Report)
Date of Report: December 10, 2021
Business Context: The registrant is a biopharmaceutical company focused on developing diagnostic tests and therapies. This filing reports a specific corporate event regarding its clinical development program rather than a standard financial reporting period.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly informational regarding a clinical trial update.
Material Changes
Clinical Program Update: The company announced that updated data from its lead KRAS-mutated metastatic colorectal cancer program will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI).
Event Details: The presentation is scheduled as a poster session for January 20-22, 2022, in San Francisco, California (virtual and in-person).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the upcoming data presentation but does not provide specific numerical guidance, financial outlook, or new risk factors within the text of this report.
Unusual Items: None reported in this specific filing.
Investor Verification Checklist
- Verify the content of the press release attached as Exhibit 99.1 for specific clinical data details.
- Monitor the ASCO-GI symposium (January 20-22, 2022) for the actual presentation of the KRAS-mutated metastatic colorectal cancer data.
- Review subsequent filings for any financial impact or strategic changes resulting from the clinical data presentation.